Intellia concluded that Rewrite’s technology can provide safe and curative genome editing treatments like the ones it is working to develop. In announcing the acquisition, Intellia also said Rewrite offered it “the potential to target diseases beyond those currently being explored in our pipeline.” Intellia isn’t yet saying which diseases those might be: “The technology is still in early-research stage, and we’ll share more as appropriate,” president and CE) John Leonard said . . .
